Valuation: Lipocine Inc.

Market Cap 11.87M 10.6M 9.79M 8.88M 16.6M 1.13B 16.88M 118M 46.66M 590M 44.55M 43.61M 1.86B P/E 2026 *
-0.93x
P/E 2027 * -1.07x
Enterprise Value 11.87M 10.6M 9.79M 8.88M 16.6M 1.13B 16.88M 118M 46.66M 590M 44.55M 43.61M 1.86B EV / Sales 2026 *
18.8x
EV / Sales 2027 * 15.9x
Free-Float
95.03%
Yield 2026 *
-
Yield 2027 * -
1 day-1.37%
1 week-7.69%
Current month-34.55%
1 month-31.10%
3 months-30.77%
6 months-40.50%
Current year-82.07%
1 week 1.4
Extreme 1.4
1.66
1 month 1.4
Extreme 1.4
3.15
Current year 1.4
Extreme 1.4
12.37
1 year 1.4
Extreme 1.4
12.37
3 years 1.4
Extreme 1.4
12.37
5 years 1.4
Extreme 1.4
32.13
10 years 1.4
Extreme 1.4
90.61
Manager TitleAgeSince
Chief Executive Officer 69 1996-12-31
Chief Tech/Sci/R&D Officer 56 2022-11-30
Chief Tech/Sci/R&D Officer 68 -
Director TitleAgeSince
Chairman 69 2014-01-07
Director/Board Member 58 2002-12-31
Chairman 73 2026-04-19
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 Buy

Director

15,970 0.1937%
9/28/26 Buy

Director

12,561 0.1524%
8/3/26 Free

Director

2,000 0.0243%
Change 5-day change 1-year change 3-year change Capi.($)
-1.37%-7.69%-50.34%-41.94% 11.87M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-0.38%+5.68%+38.39%+28.35% 23.67B
+1.19%-4.98%+26.31%-0.76% 23.97B
Average +0.11%+1.40%+38.24%+122.61% 38.31B
Weighted average by Cap. +0.39%+2.73%+46.02%+142.83%

Financials

2026 *2027 *
Net sales 631K 564K 521K 472K 883K 59.92M 898K 6.27M 2.48M 31.4M 2.37M 2.32M 98.98M 745K 665K 615K 557K 1.04M 70.72M 1.06M 7.4M 2.93M 37.05M 2.8M 2.74M 117M
Net income -12.64M -11.29M -10.43M -9.45M -17.68M -1.2B -17.97M -126M -49.69M -629M -47.45M -46.44M -1.98B -16.22M -14.48M -13.38M -12.12M -22.68M -1.54B -23.06M -161M -63.74M -807M -60.86M -59.57M -2.54B
Net Debt - -
Projected Income Statement - Annual - Lipocine Inc.
Logo Lipocine Inc.
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.
Employees
14
Date Price Change Volume
26-10-23 US$1.440 -1.37% 218,655
26-10-22 US$1.460 -8.75% 354,883
26-10-21 US$1.600 -1.23% 160,672
26-10-20 US$1.620 +5.88% 246,500
26-10-19 US$1.530 -1.92% 323,657
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lipocine Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
1.440USD
Average target price
5.000USD
Spread / Average Target
+247.22%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lipocine Inc.
  1. Stock Market
  2. Stocks
  3. LPCN Stock